ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the 19th Annual European AIDS Conference (EACS 2023) being held in Warsaw, Poland from 18-21 October 2023.
Key data to be presented at EACS 2023 by ViiV Healthcare will include:
Strengthening clinical and real-world evidence (RWE) across our treatment portfolio: New real-world findings for the long-acting regimen of Vocabria (cabotegravir injection) and Rekambys (rilpivirine long-acting injectable suspension) (CAB+RPV LA) in clinical settings across Europe will be presented at EACS. ViiV Healthcare will share 12-month European findings from the SOLAR study, the first head-to-head, phase IIIb study of the complete long-acting injectable regimen of CAB+RPV LA compared with daily oral Biktarvy (bictegravir/emtricitabine/ tenofovir alafenamide [BIC/FTC/TAF]).1
Findings for the 2-drug regimen, Dovato (dolutegravir, lamivudine [DTG/3TC]), will include three-year effectiveness, safety, and tolerability outcomes among people living with HIV in a real-world German cohort and data from a large observational cohort across Europe.2,3 Additional data to be presented will include a review of real-world experience of DTG/3TC in people living with HIV over the age of 50, as well as in treatment-naïve people with a low CD4+ cell count or high viral load at baseline.4
Long-term data in heavily treatment-experienced (HTE) populations: Long-term, five-year data from the phase III BRIGHTE clinical trial, which studied the use of Rukobia (fostemsavir) in heavily-treatment experienced populations with multi-drug resistant HIV-1, will be presented. New data will report on long-term safety and the impact of immune recovery in adults receiving fostemsavir, along with fostemsavir’s impact on immune and inflammation-related biomarkers in these patients.5,6
Advancing new mechanisms of action in HIV research: New phase IIa, proof of concept study findings will be presented from the BANNER study of N6LS (VH3810109), a novel, investigational, broadly neutralizing antibody (bNAb). Safety and tolerability findings following a single IV infusion of subcutaneous injection will be shared.7 N6LS is a component of the company’s ultra-long-acting medicine development strategy, specifically being investigated for dosing intervals of at least every four months.
Additional details to the following link: https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-23-abstracts-from-innovative-hiv-treatment-and-prevention-portfolio-at-eacs-2023/